RecruitingNCT03882827
Natural History of Duchenne Muscular Dystrophy
A Prospective, Interventional, Baseline Study In Young Male Subjects Aged From 4 to 9 Years
Sponsor
Genethon
Enrollment
220 participants
Start Date
Dec 19, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
Baseline Study on Duchenne Muscular Dystrophy (DMD) in view to collect data on the natural disease course in a cohort in young male subjects aged from 4 to 9 Years over a period of 6 to 36 months using disease appropriate evaluations.
Eligibility
Sex: MALEMin Age: 4 YearsMax Age: 9 Years
Inclusion Criteria13
- Male
- to 9 years old inclusive
- Body-weight ≤ 95th percentile or the BMI scale ≤ 95th percentile (according to validated scale in force in country site).
- Related to the DMD disease:
- Diagnosis of DMD based upon documented gene testing with detailed genotyping
- Able to achieve at inclusion and screening visits:
- NSAA (North Star Ambulatory Assessment) scale \> 18 or ≥ 16 if participant is between 4 and \< 5 years old at screening and:
- Gowers test \< or = 7 sec and/or
- Minute Walk Test (6MWT): a distance ≥ 350 meters at inclusion visit (M0)
- Ongoing corticosteroid therapy or initiation of corticosteroid therapy according to standard of care prior to Screening visit
- Related to the study protocol and ICH/GCP (Good Clinical Practice) requirements:
- Signed informed consent by at least one parent or both parents or legal guardian representative(s), when applicable and according to the country regulation
- Affiliated to or a beneficiary of a Health Care scheme (according to country regulation)
Exclusion Criteria15
- Subject will be excluded from enrolment into the study for any of the following reasons:
- Related to the DMD disease severity:
- Cardiomyopathy based on physical/cardiological examination and echocardiography with Left Ventricular Simpson biplane Ejection Fraction (LVEF) below 55%
- Respiratory Assistance: need for either a diurnal and/or a nocturnal ventilation
- Any co-morbidity (ies) and or previous or planned surgical event(s) which may interfere with DMD natural evolution and or evaluation of outcomes designed to assess DMD Natural History
- Related to specific assessments:
- Muscle testing: inability to cooperate with
- MRI: metal implants in regions of interest for the study
- Related to the study protocol and ICH/GCP requirements:
- Unwilling and/or unable to comply with all the study protocol requirements and/or procedures
- Previous inclusion to another clinical trial with an Investigational Medicinal Product (IMP), within the 3 months or IMP washout period (whichever is longer) prior to the screening visit of the study
- Previously treated with a gene therapy drug for DMD, such as:
- any AAV mediated gene transfer products or any gene editing products in a clinical trial or in a clinical setting,
- if exons skipping drug was used, the last dose of exon skipping drug within 5 half-lives prior to the screening visit
- Concomitant participation to any other interventional clinical trial
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(15)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03882827
Related Trials
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT0728718919 locations
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
NCT0645063925 locations
A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)
NCT068173829 locations
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy
NCT062802098 locations
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
NCT0599600325 locations